Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

F-18-FDG PET-CT in investigating possible malignancy associated with rheumatic disease: beware of excessive radiation.

Nuclear medicine communications·2024
Same author

Nearly double the patients and dramatic changes over 14 years of UK MRT: Internal Dosimetry Users Group survey results from 2007 to 2021.

Nuclear medicine communications·2023
Same author

Treatment of Neuroendocrine Neoplasms with Radiolabeled Peptides-Where Are We Now.

Cancers·2022
Same author

A combination of surgery, theranostics, and liquid biopsy - a personalised oncologic approach to treatment of patients with advanced metastatic neuroendocrine neoplasms.

International journal of medical sciences·2021
Same author

Spatial heterogeneity of radiolabeled choline positron emission tomography in tumors of patients with non-small cell lung cancer: first-in-patient evaluation of [<sup>18</sup>F]fluoromethyl-(1,2-<sup>2</sup>H<sub>4</sub>)-choline.

Theranostics·2020
Same author

Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with <sup>177</sup>Lu-Dotatate: an analysis of the NETTER-1 study.

European journal of nuclear medicine and molecular imaging·2020

Related Experiment Video

Updated: Jul 15, 2026

A Practical Guide for the Production and PET/CT Imaging of 68Ga-DOTATATE for Neuroendocrine Tumors in Daily Clinical Practice
08:55

A Practical Guide for the Production and PET/CT Imaging of 68Ga-DOTATATE for Neuroendocrine Tumors in Daily Clinical Practice

Published on: April 17, 2019

68Ga-DOTATATE PET in neuroectodermal tumours: first experience.

Zarni Win1, Adil Al-Nahhas, David Towey

  • 1Department of Nuclear Medicine, Hammersmith Hospital, London, UK.

Nuclear Medicine Communications
|April 7, 2007
PubMed
Summary

New PET imaging with 68Ga-DOTATATE shows superior results for malignant phaeochromocytoma compared to traditional methods. This somatostatin receptor PET tracer is valuable for detecting lesions and guiding therapy.

More Related Videos

Establishment of Orthotopic Patient-derived Xenograft Models for Brain Tumors using a Stereotaxic Device
07:44

Establishment of Orthotopic Patient-derived Xenograft Models for Brain Tumors using a Stereotaxic Device

Published on: May 2, 2025

PET and MRI Guided Irradiation of a Glioblastoma Rat Model Using a Micro-irradiator
10:48

PET and MRI Guided Irradiation of a Glioblastoma Rat Model Using a Micro-irradiator

Published on: December 28, 2017

Related Experiment Videos

Last Updated: Jul 15, 2026

A Practical Guide for the Production and PET/CT Imaging of 68Ga-DOTATATE for Neuroendocrine Tumors in Daily Clinical Practice
08:55

A Practical Guide for the Production and PET/CT Imaging of 68Ga-DOTATATE for Neuroendocrine Tumors in Daily Clinical Practice

Published on: April 17, 2019

Establishment of Orthotopic Patient-derived Xenograft Models for Brain Tumors using a Stereotaxic Device
07:44

Establishment of Orthotopic Patient-derived Xenograft Models for Brain Tumors using a Stereotaxic Device

Published on: May 2, 2025

PET and MRI Guided Irradiation of a Glioblastoma Rat Model Using a Micro-irradiator
10:48

PET and MRI Guided Irradiation of a Glioblastoma Rat Model Using a Micro-irradiator

Published on: December 28, 2017

Area of Science:

  • Nuclear Medicine
  • Oncology
  • Radiology

Background:

  • Phaeochromocytoma diagnosis often requires functional imaging beyond CT/MRI.
  • 123I-MIBG SPECT has limitations in spatial resolution.
  • Evaluating treatment response and metastasis necessitates advanced imaging techniques.

Observation:

  • A retrospective review compared CT, 123I-MIBG SPECT, and 68Ga-DOTATATE PET in five malignant phaeochromocytoma patients.
  • Analysis focused on lesion detection, extent, and imaging characteristics.
  • 68Ga-DOTATATE PET demonstrated higher sensitivity and better resolution than 123I-MIBG SPECT.

Findings:

  • 68Ga-DOTATATE PET identified lesions missed by 123I-MIBG in two patients.
  • One patient showed significantly higher uptake with 68Ga-DOTATATE.
  • All imaging modalities, including CT, were negative in one patient.

Implications:

  • Somatostatin receptor PET imaging with 68Ga-DOTATATE is valuable for managing malignant phaeochromocytoma.
  • 68Ga-DOTATATE PET is recommended for lesions with low or no MIBG uptake.
  • This tracer aids in therapy planning, particularly for Y-labelled DOTATATE treatment.